Skip to main content

Rapid Dose Therapeutics Files a Patent to Synthesize THC From CBD Using a Selective Delta 8 or Delta 9 Conversion Process

Written by Customer Service on . Posted in Public Companies.

BURLINGTON, Ontario, June 19, 2020 (GLOBE NEWSWIRE) — Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), a Canadian Life Sciences company focused on innovative drug and active ingredient delivery solutions, is pleased to announce it has filed a non-provisional patent with the USPTO for an “Apparatus for and method of converting cbd and/or cbd derivatives to at least one other type of cannabinoid and/or cannabinoid derivative such as THC”. In conjunction with McMaster University and the team lead by Dr. James McNulty, RDT has discovered a new and efficient way to create THC from CBD. This selective method can generate delta 8 or delta 9 THC.Jason Lewis, RDT SVP and co-inventor said, “This is an incredible breakthrough for RDT and the industry as a whole. Our technology could revolutionize the way synthetic THC is created so patients around the world can have access to a consistent quality of delta 8 or delta 9. Instead of the industry being dependent on the many complicated variables associated with growing cannabis and the expense of cultivating indoors, we created a method to convert hemp-derived CBD to THC. This is the innovation required to allow pharmaceutical companies to embrace cannabinoid treatments.”“This process is novel and highly efficient at selectively converting CBD isolate or distillate into synthetic THC,” said Dr. McNulty.  “Our collaboration with RDT has resulted in a transformative outcome that we are proud to be involved with.  There are numerous high yield derivatives we can control for using naturally derived CBD through the innovative conversion. My team is excited about the possibilities to provide pure cannabinoids for life science companies.”The PCT application is a follow up to the RDT provisional patent filed on April 5, 2019.  Mark Upsdell, RDT CEO, said: “Despite the current COVID situation creating delays around the globe, RDT remains committed to research and innovation.  Our filing of this patent is an indication that our continued work with McMaster is aligned with our overall strategy to create unique products aimed at improving patient outcomes.  The ability to combine this innovation with our unique QuickStrip™ delivery system will create new opportunities for RDT.”About Rapid Dose Therapeutics

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.